NEW YORK and MELBOURNE, Australia, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year ended December 31, 2016 and provide a corporate update beginning at 5:00 pm Eastern Standard Time on Sunday, February 26, 2017 and 9:00 am Australian Eastern Daylight Time on Monday, February 27, 2017.  

To access the call, dial 1 855 881 1339 (US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).

The conference identification code is 638112.

The live webcast can be accessed via:
http://webcasting.boardroom.media/broadcast/58af4d2b196ffa2970ec979c

The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.

The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com

About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.

For further information, please contact:

Julie Meldrum				
Global Head, Corporate Communications
Mesoblast Limited                  		
T: +61 3 9639 6036  			
E: julie.meldrum@mesoblast.com	

Schond Greenway
VP, Investor Relations
Mesoblast Limited
T: +1 212 880-2060 
E: Schond.Greenway@mesoblast.com